Biostock: CombiGene’s CEO on this summer’s news

Aug 10, 2021

“The gene therapy company CombiGene ended July with two significant pieces of news. Firstly, the company has started GMP production of the drug candidate CG01 for the first clinical study that begin next year. Secondly, it has obtained patents in both the US and Russia for the candidate. BioStock got in touch with CEO Jan Nilsson to find out more.”

Read the article >>

About CombiGene

CombiGene’s vision is to provide patients affected by severe life-altering diseases with the prospect of a better life through novel gene therapies. CombiGene’s business concept is to develop effective gene therapies for severe life-altering diseases where adequate treatment is currently lacking. Development assets are sourced from an external research network and developed to achieve clinical proof of concept. Drug candidates for common diseases will be co-developed and commercialized through strategic partnerships, while the company may manage this process on its own for drugs targeting niched patient populations.

The Company has an exclusive collaboration and licensing agreement for the CG01 project with Spark Therapeutics.

The company is public and listed on the Swedish marketplace Nasdaq First North Growth Market and the company’s Certified Advisor is FNCA Sweden AB, +46 (0)852 80 03 99 info@fnca.se.

 

 

CombiGene AB, Agavägen 52A, SE-181 55 Lidingö

 

Linked In     Twitter      Facebook

CombiGene’s lead project CG01 has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 823282